FDA Annual Report

Total Voting Rights

First Patient Safety

Recruitment of Second Patient for Clinical Trials

Conversion of convertible loan notes

Institutional investment

First-in-Human Treatment with HG-CT-1

Issue of convertible loan notes

Total Voting Rights

Placing to raise £340,000

Change of Company Secretary and Registered Office

Total Voting Rights

Opening of First Clinical Site

Ultrafast CAR-T Manufacturing

Admission of New Ordinary Shares and New ISIN

Result of Extraordinary General Meeting

Site Initiation Visit Completed

CBR Macrophage Delivery Update

Total Voting Rights

Notice of Extraordinary General Meeting

IRB Approval for Phase I Clinical Trial

Institutional Investment

Schedule for Phase I Clinical Trial Opening

Strategic Investment from Prevail Partners, LLC

Half-year Report

FLT3 Assay Ready for Phase I Trials at MD Anderson

CDX Development Update

Presentation at CBD S&T Conference

Result of Annual General Meeting

Operations Update

Posting of Annual Report & Notice of AGM

Final Results

Total Voting Rights

Placing to Raise US$4.2 million

CBR Brain Delivery

CBR Intranasal Delivery

FDA Consents to Phase I Trials of HEMO-CAR-T

Approval and Issuance of U.S. Conditioning Patent

Submission of Complete Response to Clinical Hold

HEMO-CAR-T Process Qualification Run Completed

Placing to Raise £534,375

CBR Expanded to Treatment of Cancer

Lentivirus Re-manufacturing Completed

Total Voting Rights

Half-year Report

Strategic Investment from Prevail Partners, LLC

Clinical Hold Lift Plan is accepted by FDA

Full FDA Review for HEMO-CAR-T IND

Result of Annual General Meeting

Posting of Annual Report & Notice of AGM

Clinical Hold on IND for HEMO-CAR-T

Submission of IND for HEMO-CAR-T